Ramona K Hilgenkamp

US Patent:

20120040949, Feb 16, 2012

Filed:

Aug 11, 2011

Appl. No.:

13/207481

Inventors:

Steven Joseph Berthel - Mendham Township NJ, US
Roland Joseph Billedeau - Clifton NJ, US
Christine E. Brotherton-Pleiss - Sunnyvale CA, US
Fariborz Firooznia - Florham Park NJ, US
Stephen Deems Gabriel - Morristown NJ, US
Xiaochun Han - Cedar Grove NJ, US
Ramona Hilgenkamp - Montclair NJ, US
Saul Jaime-Figueroa - Morris Plains NJ, US
Buelent Kocer - Hoboken NJ, US
Francisco Javier Lopez-Tapia - Mahwah NJ, US
Yan Lou - Clifton NJ, US
Lucja Orzechowski - Kinnelon NJ, US
Timothy D. Owens - Jersey City NJ, US
Jenny Tan - New Providence NJ, US
Peter Michael Wovkulich - Nutley NJ, US

International Classification:

A61K 31/502
C07D 413/14
C07D 403/14
C07D 487/10
A61P 37/00
C07D 491/107
A61K 31/5377
A61K 31/541
A61K 31/501
A61P 29/00
C07D 401/14
C07D 417/14

US Classification:

51421016, 544237, 544119, 544114, 544 582, 544238, 514248, 5142345, 51421021, 5142352, 5142282, 514249, 51425204

Abstract:

This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I:wherein, variables X, R, and Y, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

US Patent:

20130178461, Jul 11, 2013

Filed:

Mar 1, 2013

Appl. No.:

13/781815

Inventors:

Roland Joseph Billedeau - Santa Clara CA, US
Christine E. Brotherton-Pleiss - Sunnyvale CA, US
Fariborz Firooznia - Florham Park NJ, US
Stephen Deems Gabriel - Morristown NJ, US
Xiaochun Han - Cedar Grove NJ, US
Ramona Hilgenkamp - Montclair NJ, US
Saul Jaime-Figueroa - Morris Plains NJ, US
Buelent Kocer - Shanghai, CN
Francisco Javier Lopez-Tapia - Mahwah NJ, US
Yan Lou - Pleasanton CA, US
Lucja Orzechowski - Kinnelon NJ, US
Timothy D. Owens - San Carlos CA, US
Jenny Tan - New Providence NJ, US
Peter Michael Wovkulich - Nutley NJ, US

Assignee:

Hoffmann-La Roche Inc. - Nutley NJ

International Classification:

C07D 401/14
C07D 405/14
C07D 487/04

US Classification:

51421021, 544114, 5142352, 544238, 51425204, 514249

Abstract:

This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I:wherein, variables X, R, and Y, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

US Patent:

20150210704, Jul 30, 2015

Filed:

Sep 10, 2013

Appl. No.:

14/427501

Inventors:

- Nutley NJ, US
Ramona Hilgenkamp - Montclair NJ, US
Rama K. Kondru - Morris Plains NJ, US
Francisco Javier Lopez-Tapia - Honolulu HI, US
Yan Lou - Pleasanton CA, US

Assignee:

Hoffmann-La Roche Inc. - Nutley NJ

International Classification:

C07D 487/04
C07D 405/14
C07D 401/14

Abstract:

This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.